370 related articles for article (PubMed ID: 35964134)
1. Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment.
Jiang J; Ying H
J Exp Clin Cancer Res; 2022 Aug; 41(1):244. PubMed ID: 35964134
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr Virus Induces Adipocyte Dedifferentiation to Modulate the Tumor Microenvironment.
Liu SC; Tsang NM; Lee PJ; Sui YH; Huang CH; Liu TT
Cancer Res; 2021 Jun; 81(12):3283-3294. PubMed ID: 33824135
[TBL] [Abstract][Full Text] [Related]
3. The immune escape mechanism of nasopharyngeal carcinoma.
Li X; Guo Y; Xiao M; Zhang W
FASEB J; 2023 Jul; 37(7):e23055. PubMed ID: 37358482
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.
Li W; Lv S; Liu G; Lu N; Jiang Y; Liang H; Xia W; Xiang Y; Xie C; He J
Front Immunol; 2023; 14():1124066. PubMed ID: 36860875
[TBL] [Abstract][Full Text] [Related]
7. Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities.
Liu Q; Bode AM; Chen X; Luo X
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189023. PubMed ID: 37979733
[TBL] [Abstract][Full Text] [Related]
8. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.
Tsang CM; Tsao SW
Virol Sin; 2015 Apr; 30(2):107-21. PubMed ID: 25910483
[TBL] [Abstract][Full Text] [Related]
9. Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer.
Looi CK; Foong LC; Chung FF; Khoo AS; Loo EM; Leong CO; Mai CW
Cell Biol Toxicol; 2023 Dec; 39(6):2501-2526. PubMed ID: 37755585
[TBL] [Abstract][Full Text] [Related]
10. Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection.
Liu X; Deng Y; Huang Y; Ye J; Xie S; He Q; Chen Y; Lin Y; Liang R; Wei J; Li Y; Zhang J
Curr Oncol; 2022 Aug; 29(9):6035-6052. PubMed ID: 36135044
[TBL] [Abstract][Full Text] [Related]
11. Influence of Epstein-Barr virus and human papillomavirus infection on macrophage migration inhibitory factor and macrophage polarization in nasopharyngeal carcinoma.
Feng G; Xu Y; Ma N; Midorikawa K; Oikawa S; Kobayashi H; Nakamura S; Ishinaga H; Zhang Z; Huang G; Takeuchi K; Murata M
BMC Cancer; 2021 Aug; 21(1):929. PubMed ID: 34407796
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.
Han S; Tay JK; Loh CJL; Chu AJM; Yeong JPS; Lim CM; Toh HC
Front Immunol; 2021; 12():734293. PubMed ID: 34956172
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma.
Yoshizaki T; Kondo S; Endo K; Nakanishi Y; Aga M; Kobayashi E; Hirai N; Sugimoto H; Hatano M; Ueno T; Ishikawa K; Wakisaka N
Cancer Sci; 2018 Feb; 109(2):272-278. PubMed ID: 29247573
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
Xue F; He X
Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
16. NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma.
Verhoeven RJ; Tong S; Zhang G; Zong J; Chen Y; Jin DY; Chen MR; Pan J; Chen H
J Virol; 2016 Jul; 90(14):6475-88. PubMed ID: 27147748
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus infection and nasopharyngeal carcinoma.
Tsao SW; Tsang CM; Lo KW
Philos Trans R Soc Lond B Biol Sci; 2017 Oct; 372(1732):. PubMed ID: 28893937
[TBL] [Abstract][Full Text] [Related]
18. Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma.
Ka-Yue Chow L; Lai-Shun Chung D; Tao L; Chan KF; Tung SY; Cheong Ngan RK; Ng WT; Wing-Mui Lee A; Yau CC; Lai-Wan Kwong D; Ho-Fun Lee V; Lam KO; Liu J; Chen H; Dai W; Lung ML
EBioMedicine; 2022 Dec; 86():104357. PubMed ID: 36371985
[TBL] [Abstract][Full Text] [Related]
19. Association of Plasma Epstein-Barr Virus LMP1 and EBER1 with Circulating Tumor Cells and the Metastasis of Nasopharyngeal Carcinoma.
Sun L; Wang Y; Shi J; Zhu W; Wang X
Pathol Oncol Res; 2020 Jul; 26(3):1893-1901. PubMed ID: 31832991
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomics of Epstein-Barr virus aids to the classification of T-cell evasion in nasopharyngeal carcinoma.
Mahajan S; Bongaerts M; Hardillo J; Tsang A; Lo KW; Kortleve D; Ma B; Debets R
Curr Opin Immunol; 2023 Aug; 83():102335. PubMed ID: 37235920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
